10-Q: INVO Fertility Narrows Focus, Reports Q2 Losses

INVO Fertility, Inc. divests majority stake in NAYA Therapeutics to refocus on core fertility business, reporting significant net losses and ongoing liquidity challenges in its latest quarterly filing.

Summary

• INVO Fertility, Inc. (formerly NAYA Biosciences, Inc.) has strategically divested 80.1% of its NAYA Therapeutics (NTI) subsidiary in Q2 2025 to concentrate solely on the fertility market.
• The company reported a substantial net loss of $22.7 million for the six months ended June 30, 2025, a significant increase from $3.8 million in the same period of 2024.
• Total revenue for the six months ended June 30, 2025, modestly increased to $3.5 million from $3.4 million in 2024, primarily driven by clinic revenue.
• Operating expenses surged due to a $16.0 million impairment loss, including $14.6 million on NTI goodwill and $1.4 million on a noncompetition agreement related to the Wisconsin Fertility Institute (WFI).
• The company settled a legal dispute with Dr. Elizabeth Pritts, related to the WFI acquisition, agreeing to a $5.0 million payment schedule through December 2026, resulting in a $0.7 million gain on settlement.
• Cash and cash equivalents stood at $0.5 million as of June 30, 2025, down from $0.6 million at December 31, 2024, and $0.9 million at June 30, 2024.
• Net cash used in operating activities increased to $5.3 million for the first six months of 2025, compared to $1.7 million in the prior year, primarily due to the NTI consolidation and subsequent divestiture losses.
• The company completed a public offering in January 2025, raising $8.7 million in net proceeds, which were partially used to redeem $4.0 million of preferred stock and repay approximately $1.1 million in debt.
• Two reverse stock splits were enacted: 1-for-12 in March 2025 and 1-for-3 in July 2025, alongside an increase in authorized common stock to 50,000,000 shares.
• The Series C-2 Preferred Stock was reclassified from mezzanine equity to permanent equity after removing certain redemption rights.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant net losses, increased cash burn, and a going concern warning from auditors. While the strategic refocus and settlement of litigation are positive steps, the financial health remains precarious, necessitating further capital raises. The substantial non-cash impairment charges also weigh heavily on the financial results.

Positives

• Strategic divestiture of NAYA Therapeutics allows for exclusive focus on the core fertility marketplace, aligning business activities.
• Modest increase in total revenue for the six months ended June 30, 2025, driven by clinic revenue growth.
• Successful settlement of the Dr. Pritts litigation, resolving a significant dispute, albeit with a payment obligation.
• Successful public offering in January 2025 raised $8.7 million in net proceeds, providing capital for operations and debt/preferred stock redemption.
• The Wisconsin Fertility Institute (WFI) acquisition continues to serve as a solid foundation and significant source of revenue for the fertility business.

Negatives

• Reported a substantial net loss of $22.7 million for the six months ended June 30, 2025, significantly higher than $3.8 million in the prior year.
• Incurred a large non-cash impairment loss of $16.0 million, primarily from NTI goodwill and the WFI noncompetition agreement.
• Experienced a significant loss from discontinued operations of NTI totaling $16.5 million, including the goodwill impairment.
• Cash balance decreased to $0.5 million, and net cash used in operating activities increased to $5.3 million, indicating continued high cash burn.
• Negative working capital worsened to $6.3 million as of June 30, 2025, from $5.6 million at December 31, 2024.
• Stockholders' equity significantly decreased to $2.6 million from $12.7 million over the six-month period.
• Product revenue from INVOcell device sales decreased from $67,763 in 2024 to $47,192 in 2025 for the six-month period.
• Increased labor costs in the Wisconsin clinic contributed to higher cost of revenue.

Risks

• The company's independent registered public accounting firm issued a going concern qualification, expressing substantial doubt about its ability to continue operations.
• Continued dependence on raising additional capital through debt and/or equity financings, which may not be available on reasonable terms or at all.
• Significant accumulated deficit of $90.2 million as of June 30, 2025, indicating a history of operating losses.
• Material weaknesses in internal control over financial reporting, including limited segregation of duties and lack of adequate accounting resources for complex transactions, could lead to material misstatements.
• The $5.0 million settlement payment to Dr. Pritts is a significant financial obligation, with scheduled payments extending through December 2026.
• Forward-looking statements involve substantial known and unknown risks and uncertainties, and actual results may differ materially.
• Risks related to market acceptance of products and intellectual property.

Future Outlook

The company expects its fertility operations to make further operational progress for the remainder of 2025. It plans to continue actively pursuing additional acquisitions of established and profitable IVF clinics to accelerate growth and achieve cash flow break-even and profitability. The company will also continue to grow INVOcell sales within its own clinics and to third-party clinics, and seek out additional innovative technologies to enhance clinic operations and patient benefits. The company anticipates benefiting from the ongoing growth in the ART market due to increasing infertility rates, patient awareness, and improving financial incentives.

Management Comments

• "Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by our INVOcell medical device (INVOcell) and US-based, profitable in vitro fertilization (IVF) clinics."
• "We remain enthusiastic about [NTI's] prospects and will retain a minority stake in NAYA Therapeutics, which we hope to monetize in the future through value appreciation that could be generated from the clinical development of its bifunctional antibodies."
• "Our revised corporate structure is intended to enable both businesses to focus on their respective opportunities and operations, with the existing management team and our board of directors continuing to lead the public company and its focus on the fertility marketplace."
• "Although we anticipate our clinic operations will dominate our commercial efforts and revenue, we also will continue to work on growing INVOcell, both within our own clinics as well as to third party fertility clinics."
• "We have resumed active pursuit of additional acquisitions of established and profitable IVF clinics with a view to accelerate our growth and drive our overall business to beyond cash flow break even and to profitability."

Industry Context

The global Assisted Reproductive Technology (ART) market is a large and growing multi-billion-dollar industry, driven by increasing infertility rates, greater patient awareness, and improving financial incentives like insurance and governmental assistance. Despite this growth, the market remains vastly underserved, with a high percentage of patients untreated due to capacity constraints and cost barriers. The company's strategy to acquire and operate fertility clinics, including INVO Centers and profitable IVF clinics, directly addresses the market's imbalance between supply and demand, particularly in underserved secondary markets. Its INVOcell technology offers a potentially more affordable and accessible alternative to traditional IVF, aligning with the broader trend of democratizing fertility care.

Comparison to Industry Standards

• The company's INVOcell device and the IVC procedure it enables are stated to deliver comparable pregnancy success and live birth rates as traditional IVF, but at a lower cost, positioning it as a competitive alternative to standard IVF clinics.
• The acquisition of profitable IVF clinics like Wisconsin Fertility Institute (WFI) is a common strategy in the fragmented fertility market to gain scale and established patient flows, similar to consolidation trends seen among larger fertility clinic networks.
• The company's focus on underserved secondary markets for new INVO Centers differentiates its expansion strategy from competitors who might concentrate on primary metropolitan areas, potentially allowing for higher market penetration where competition is less intense.
• The shift from a medical device company to a healthcare services company, emphasizing clinic operations, reflects a broader industry trend where technology providers integrate vertically to capture more value across the patient journey, similar to models adopted by larger fertility service providers like Progyny or CooperSurgical (though INVO is much smaller in scale).

Corporate Governance

Legal Proceedings

• A complaint was filed on May 7, 2025, by Dr. Elizabeth Pritts and the Pritts Trust against the company and its subsidiaries, alleging breach of contract, breach of implied covenant of good faith and fair dealing, tortious interference with contract, and unjust enrichment related to the Wisconsin Fertility Institute acquisition.
• On May 14, 2025, the company entered into a binding term sheet to settle all disputes with Dr. Pritts and the Pritts Trust, agreeing to pay $5,000,000 in installments through December 31, 2026.
• The settlement includes the termination of all employment, consulting, and similar agreements with Dr. Pritts, and customary indemnification and release of claims.

Related Party Transactions

• The company has outstanding demand notes totaling $880,000 from a related party, JAG Multi Investments LLC (JAG), in which the company's chief financial officer is a beneficiary but has no control over investment decisions. These notes accrue 10% annual interest.
• Additional demand promissory notes totaling $220,000 were issued in Q4 2022 to the company's chief executive officer and an entity controlled by its chief financial officer, accruing 10% annual interest.
• As of June 30, 2025, the total outstanding balance for these related party demand notes, including principal and accrued interest, was $1,085,010.
• On August 13, 2025, the JAG Notes were amended to extend the maturity date to September 30, 2025, with potential further extensions based on payments, and became convertible into common stock at $2.00 per share. A warrant to purchase 150,000 shares at $2.00 per share was also issued to JAG.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future equity financings, warrant exercises, and convertible debt conversions. The substantial net losses and going concern warning indicate a high risk to investment value. Reverse stock splits aim to maintain Nasdaq listing, but do not fundamentally change underlying value.
• **Employees**: The strategic refocus on fertility may provide clearer direction and stability for employees in that segment. The settlement of the Dr. Pritts litigation resolves uncertainty for WFI staff. The increase in the stock incentive plan provides potential for equity compensation.
• **Customers (Patients)**: The company's focus on expanding access to ART care, including through INVO Centers and acquired IVF clinics, aims to benefit patients by increasing availability and potentially offering more affordable options. The INVOcell device continues to offer a unique treatment solution.
• **Creditors**: The company's liquidity challenges and reliance on new financing pose risks. Debt restructuring and amendments, such as with Decathlon Alpha V LP and JAG, indicate ongoing efforts to manage obligations, but also highlight the company's financial strain.
• **Suppliers**: The company's dependence on third-party manufacturers and specialists for INVOcell production means their financial health and operational stability could indirectly impact suppliers through continued business or potential payment delays if liquidity issues persist.

Next Steps

• Actively pursue the acquisition of additional U.S.-based, profitable IVF clinics to accelerate growth and achieve cash flow break-even and profitability.
• Continue to grow INVOcell sales within its own clinics and to third-party fertility clinics.
• Seek out additional, innovative fertility-focused technologies to license or acquire for use within its operating clinics.
• Finalize and execute the Settlement Agreement and related documentation with Dr. Pritts in the third quarter of 2025.
• Continue efforts to improve internal control over financial reporting, including addressing limited segregation of duties and lack of adequate accounting resources.
• Make scheduled settlement payments to Dr. Pritts through December 31, 2026, with potential acceleration based on future funding proceeds.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial net loss of $22.7 million, a significant increase in cash used in operating activities, and a negative working capital position. The 'going concern' qualification from auditors indicates a high risk of business failure. While the strategic refocus on fertility and the settlement of the Pritts litigation are positive operational developments, they do not offset the immediate and pressing liquidity issues. The continuous need for capital raises, coupled with significant dilution from recent offerings and warrant exercises, suggests that existing shareholders will bear the brunt of the company's financial struggles. The high impairment charges also reflect past overvaluations or failed ventures. Until the company demonstrates a clear path to sustainable profitability and positive cash flow, the investment risk is exceptionally high.

Keywords

Fertility, IVF, INVOcell, Assisted Reproductive Technology, Clinic Services, Medical Device, SEC Filing, Quarterly Report, Healthcare, Biotechnology